CANY
SPPI

Caxton Associates (New York)’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Caxton Associates (New York)’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-107,135
Closed -$84K – 720
2022
Q2 		$84K Hold
107,135
– – 0.01% 520
2022
Q1 		$138K Sell
107,135
-56,961
-35% -$52.5K 0.01% 468
2021
Q4 		$208K Buy
+164,096
New +$293K 0.02% 487

Other funds holding SPPI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Caxton Associates (New York)'s SPPI Position: Q3 2022 in Review

Caxton Associates (New York) sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2022, closing a stake of 107,135 shares — an estimated $84K sold.

Caxton Associates (New York) first reported a position in SPPI in Q4 2021 and held it in 3 quarters. The position peaked at $208K in Q4 2021. 75 funds tracked by Wall St. Rank hold SPPI as of Q3 2022.

  • Caxton Associates (New York) reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 107,135 Spectrum Pharmaceuticals Inc shares in Q3 2022, an estimated $84K.
  • Caxton Associates (New York) first reported a position in Spectrum Pharmaceuticals Inc in Q4 2021 and held it in 3 quarters.
  • Caxton Associates (New York)'s Spectrum Pharmaceuticals Inc position peaked at $208K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.